Overview
Bijuva is a combination product containing estradiol and progesterone FDA approved for the treatment of moderate to severe vasomotor symptoms due to menopause.

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Bijuva, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs OR Authorization may be granted if the member meets all following criteria and documentation has been submitted:
1. Member is at least 18 years of age
2. Member has diagnosis of moderate to severe vasomotor symptoms due to menopause
3. Member has had an inadequate response, intolerance or a contraindication to an estrogen and progesterone formulation taken concurrently as separate agents

Limitations
1. Approvals will be granted for 12 months

References
1. Bijuva (estradiol and progesterone) [prescribing information]. Boca Raton, FL: Therapeutics MD, Inc; March 2019

**Review History**
09/18/19 – Reviewed

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.